✦ LIBER ✦

Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma

✍ Scribed by Keichiro Mihara; Kazuyoshi Yanagihara; Misato Takigahira; Akira Kitanaka; Chihaya Imai; Joyeeta Bhattacharyya; Takanori Kubo; Yoshifumi Takei; Shin’ichiro Yasunaga; Yoshihiro Takihara; Akiro Kimura

Book ID: 108676886
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 587 KB
Volume: 151
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2010.08297.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of relapsed B-cell non-Hodgkin

Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy

✍ van der Kolk, L E; Grillo-López, A J; Baars, J W; van Oers, M H J 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 132 KB

Therapy of human B-cell lymphoma bearing

Therapy of human B-cell lymphoma bearing scid mice is more effective with anti-CD19-and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone

✍ David J. Flavell; Deborah A. Boehm; Loretta Emery; Armorel Moss; Alan Ramsay; So 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 French ⚖ 885 KB

The CD19+ CD38+ human Burkitt's lymphoma cell line Ramos grows aggressively when injected intravenously (i.v.) into severe combined immunodeficient (SCID) mice, killing 100% of animals within a 3 3 4 2 day period with widely disseminated disease. Treatment commencing 7 days after i.v. injection of R